Multiple myeloma-initiating cells
- 1.7k Downloads
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells. As in other cancers, MM plasma cells are thought to be derived from MM-initiating cells, although these remain unidentified. MM patients harbor phenotypic CD19+ B cells expressing the immunoglobulin gene sequence and the idiotype unique to the individual myeloma clone. Some previous studies have reported that CD19+ clonotypic B cells can serve as MM-initiating cells. However, we and another group have recently showed that CD19+ B cells from many MM patients do not reconstitute MM disease upon transplantation into NOD/SCID IL2Rγc−/− mice. In the SCID-rab and SCID-hu models, which enable engraftment of human MM in vivo, CD19−CD38++ plasma cells engrafted and rapidly propagated MM, while engraftment of CD19+ B cells was not detected. Both CD138− and CD138+ plasma cells have the potential to propagate MM clones in vivo in the absence of CD19+ B cells. Distinct from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential.
KeywordsMultiple myeloma Stem cell Progenitor cell Xenotransplant CD138
CD19+ clonotypic B cells in MM patients
MM-initiating potentials of CD19+ clonotypic B cells could not be detected by xeno-transplant assay using NOD/SCIDXIL2Rγ−/− mice in many MM patients
CD19+ B cells isolated from MM patients could reportedly generate MM disease upon transplantation into NOD/SCID mice in a few MM patients [11, 12, 13, 14], indicating that clonotypic CD19+ B cells served as MM progenitor cells in these patients. These results suggested that CD19+ clonotypic B cells are important therapeutic targets in MM therapy. However, B cell depletion by means of rituximab in MM patients was not clinically effective in most cases, at least for short periods . It is therefore still unclear whether CD19+ or CD20+ clonogenic MM progenitor cells are responsible for disease progression and maintenance.
Taken together, the presence of CD19+ MM-initiating cells could not be proven by xeno-transplant assay using NOG mice as recipients in many of MM patients, although it is certain that there are small numbers of MM cases in which CD19+ B cells has MM-initiating potential as previously reported.
CD19−CD38++ MM plasma cells, but not CD19+ B cells, can initiate and maintain MM disease in the SCID-hu/rab system
SCID-hu or SCID-rab model has been used for reconstitution of MM disease in mice [18, 19]. In Japan, only SCID-rab model is permitted to perform. A human or rabbit bone fragment is inserted under the skin of a SCID mouse more than 4 weeks before transplantation of MM cells. Samples from MM patients are injected into the human or rabbit bone, and the engraftment and expansion of MM cells can be detected by measuring human immunoglobulin light chain (IgL) κ and λ in serum of the recipient mouse. We first transplanted whole BM cells from MM patients and engraftment of MM cells was monitored by measuring human IgLκ and λ in serum of the recipient mice. Engraftment and expansion of MM cells were observed in 5 out of 12 cases. Rabbit BM was analyzed 12 weeks or more after transplant to determine whether engraftment of not only MM plasma cells but also CD19+ B cells had taken place. Robust engraftment of human CD38++ MM plasma cells expressing the monotypic immunoglobulin light chain and containing both CD138− and CD138+ cells was detected in the rabbit BM, but no human CD19+ B cells were detected. These results indicate that CD19−CD38++ plasma cells could engraft and expand at least for several months without engraftment of CD19+ B cells. The same results have been recently reported using SCID-hu system by Kim and Weissman .
Taken together, our findings show that MM-initiating cells are present in plasma cells in most MM patients. Both CD138− and CD138+ plasma cells have potential to propagate and maintain MM clones for at least several months without the need for CD19+ clonotypic B cells (Fig. 5).
Future prospects about studies about MM-initiating cells or MM stem cells
It is still unclear whether only a subset of plasma cells has MM-initiating potential or many plasma cells have it. It is well known that the survival of MM plasma cells is highly dependent on microenvironment [23, 24]. Thus, it may be possible that many plasma cells, even if not all, can acquire MM-initiating potential by being at an appropriate location namely “niche”. It is undoubtedly important to know more about the niche of MM plasma cells or MM-initiating cells. For long years, many researchers have been used “bone marrow stroma cell”, which are the mixture of non-hematopoietic cells in BM, as supporting cells for MM plasma cells. However, there has been only a little information about niche cells for MM plasma cells. Recently, Iriuchishima et al.  have reported interesting findings about niche for MM cells. By transplanting GFP-expressing human MM cell line into NOG mice, they found that transplanted MM cells preferentially engrafted at the metaphyseal region of the BM endosteum and formed a complex with osteoblasts and osteoclasts, suggesting that MM plasma cells have the character similar to quiescent hematopoietic stem cells (HSCs). Another interesting finding in this report was that a subpopulation of MM cells expressed VE-cadherin after transplantation and formed endothelial-like structures in the BM, and VE-cadherin(+) MM cells were chemo-resistant, hypoxic, and HIF-2alpha-positive compared to the VE-cadherin(−) population, suggesting the possibility of the existence of VE-cadherin(+) MM stem cells. Accumulating knowledge about stem cell niche obtained from HSC research  may be applied to studies of MM stem cells.
CD19+ B cells in a few MM patients generated MM disease upon transplantation into NOD/SCID mice [11, 12, 13, 14], indicating that CD19+ B cells of these MM patients definitely contain MM progenitor cells. In our experiments  and those by Kim et al. , CD19+ B cells from MM patients never induced MM disease upon transplantation into NOG mice. However, this does not necessarily mean that CD19+ clonotypic B cells cannot be MM progenitor cells in those MM patients. It should be noted that there are many difficulties involved in the engraftment of human cells in xeno-graft models. For example, mouse IL6, which is one of the major growth factors for plasma cells, does not transduce its signals through human IL6 receptors, and probably other factors also lack inter-species cross-reactivity between human and mice. This means that MM progenitor cells can be detected in xeno-graft assays only when they can survive independently of human IL6 or other human factors. Thus, CD19+ B cells from advanced MM patients may be independent of several survival factors and effectively engraft and propagate MM disease upon transplant into immuno-deficient mice. In addition, signals from B cell receptors (BCRs) on clonotypic CD19+ B cells need to be taken into consideration. When BCRs of clonotypic CD19+ B cells show very high affinity to xeno-antigen in mice, they may be depleted and cannot survive in xeno-graft models. Thus, assuming that CD19+ MM progenitor cells are present, they can be detected in xeno-graft assays only when their BCRs are suitable for survival in mice.
While xeno-transplant system is hard to utilize in research for the stem cells of B cell malignancies for the reason as described above, it is an extremely excellent tool for the analysis of human hematopoietic stem cells. Numbers of excellent studies about normal or malignant hematopoietic stem cells have been done with xeno-transplantation to NOD/SCID or NOG mice. It is thus possible for us to analyze whether hematopoietic stem cells are normal in MM or other B cell malignancies. Kikushige and Akashi  have recently reported surprising results of the analysis of HSCs in CLL patients. They found that HSCs purified from patients with CLL displayed lymphoid-lineage gene priming and produced a high number of polyclonal B cell progenitors. Strikingly, their maturation into B cells was restricted always to mono- or oligo-clones with CLL-like phenotype in xenogeneic recipients. These results let us prompted us to perform the same analysis of HSCs from MM patients.
How to target MM-initiating cells in bone marrow
MM-initiating plasma cells should be considered important therapeutic targets, although we have not identified which plasma cells have MM-initiating potential. The Hedgehog signaling pathway was reported to be a promising candidate as a therapeutic target against clonogenic MM cells . In addition, it is also important to understand the mechanisms involved in how the BM microenvironment supports clonogenic MM plasma cells and targets them. The Notch signaling pathway may be a good candidate for such a target .
In addition to these, therapy with monoclonal antibody against MM plasma cells should be a promising strategy . Since the mechanisms of antibody drug to kill tumor cells are totally different from those of other drugs such as chemotherapeutic drugs, proteasome inhibitors, and IMIDs, combination of antibody drugs with these conventional therapies should be effective. In fact, the addition of rituximab to CHOP chemotherapy increased the cure rate of lymphoma patients. Results of clinical trials with anti-CS1 antibody is very promising , and thereby it is expected to be approved as the first antibody drug against MM. In addition, several other antibodies, for example anti-CD38 mAb , have been also proved to be effective in MM patients.
We recently identified CD48 as a novel therapeutic target that is highly expressed on MM plasma cells in almost all MM patients (Fig. 5) . In 22 out of 24 MM patients, CD48 was expressed on more than 90 % of MM plasma cells at significantly higher levels than it was on normal lymphocytes and monocytes. An anti-CD48 mAb that was newly generated by us induced antibody-dependent cell-mediated cytotoxicity and marked complement-dependent cytotoxicity against not only MM cell lines but also primary MM plasma cells in vitro. Administration of the anti-CD48 mAb significantly inhibited tumor growth in SCID mice inoculated subcutaneously with MM cells. Furthermore, anti-CD48 mAb treatment inhibited growth of MM cells transplanted directly into BM of the mice. Finally and importantly, we demonstrated that the anti-CD48 mAb did not damage normal CD34+ hematopoietic stem/progenitor cells. It should be noted that the expression patterns of CD48 in human hematopoietic progenitor cells are largely different form murine ones. While CD48 is expressed on almost all of c-kit+Sca-1+lin− mouse HSCs except for CD150+ long term-HSCs, in most of human CD34+ hematopoietic stem cells do not express or expressed at very low levels of CD48. These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM.
Different from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. This suggests that strategies for targeting MM-initiating cells should be different from those for leukemia-stem cells. On the other hand, some reports suggested common characters between MM plasma cells and hematopoietic stem cells. Especially, both of them highly prefer BM microenvironment. We now need to know how BM microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model.